Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Bailey, Kent ^a   Kirk, Amber ^a   Naik, Shruthi ^a   Nace, Rebecca ^a   Steele, Michael B ^a   Suksanpaisan, Lukkana ^a   Li, Xing ^a   Federspiel, Mark J ^a   Peng, Kah Whye ^a   Kirk, David ^b   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

^b Consulpack Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; MATHEMATICAL MODEL; MOUSE; MYELOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLASMACYTOMA; SINGLE DRUG DOSE; SURVIVAL PREDICTION; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; VIRUS TRANSMISSION;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, SCID; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR BURDEN; VERO CELLS; VESICULOVIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891693437     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073759     Document Type: Article

References (32)

1. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
2. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH (2010) Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine & growth factor reviews 21: 85-89.
3. Dingli D, Cascino MD, Josic K, Russell SJ, Bajzer Z (2006) Mathematical modeling of cancer radiovirotherapy. Math Biosci 199: 55-78.
4. Bajzer Z, Carr T, Josic K, Russell SJ, Dingli D (2008) Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol 252: 109-122.
5. Dingli D, Offord C, Myers R, Peng KW, Carr TW, et al. (2009) Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther 16: 873-882.
6. Biesecker M, Kimn JH, Lu H, Dingli D, Bajzer Z (2010) Optimization of virotherapy for cancer. Bull Math Biol 72: 469-489.
7. Paiva LR, Binny C, Ferreira SC, Jr., Martins ML (2009) A multiscale mathematical model for oncolytic virotherapy. Cancer Res 69: 1205-1211.
8. Eftimie R, Dushoff J, Bridle BW, Bramson JL, Earn DJ (2011) Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions. Bull Math Biol 73: 2932-2961.
9. Komarova NL, Wodarz D (2010) ODE models for oncolytic virus dynamics. J Theor Biol 263: 530-543.
10. Wodarz D (2003) Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther 14: 153-159.
11. Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, et al. (2012) Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. Gene therapy 19: 543-549.
12. Mok W, Stylianopoulos T, Boucher Y, Jain RK (2009) Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 15: 2352-2360.
13. Paiva LR, Martins ML, Ferreira SC (2011) Questing for an optimal, universal viral agent for oncolytic virotherapy. Physical review E, Statistical, nonlinear, and soft matter physics 84: 041918.
14. Tian JP (2011) The replicability of oncolytic virus: defining conditions in tumor virotherapy. Math Biosci Eng 8: 841-860.
15. Wein LM, Wu JT, Kirn DH (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer research 63: 1317-1324.
16. Wodarz D (2001) Viruses as antitumor weapons: defining conditions for tumor remission. Cancer research 61: 3501-3507.
17. Wodarz D, Hofacre A, Lau JW, Sun Z, Fan H, et al. (2012) Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PLoS computational biology 8: e1002547.
18. Wodarz D, Komarova N (2009) Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection. PloS one 4: e4271.
19. Wu JT, Byrne HM, Kirn DH, Wein LM (2001) Modeling and analysis of a virus that replicates selectively in tumor cells. Bulletin of mathematical biology 63: 731-768.
20. Wu JT, Kirn DH, Wein LM (2004) Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bulletin of mathematical biology 66: 605-625.
21. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM (1988) Animal model of human disease. Multiple myeloma. The American journal of pathology 132: 593-597.
22. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, et al. (1996) Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 10: 866-876.
23. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, et al. (2012) Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26: 1870-1878.
24. Naik S, Nace R, Barber GN, Russell SJ (2012) Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther 19: 443-450.
25. Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD (2011) Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clinical cancer research : an official journal of the American Association for Cancer Research 17: 4214-4224.
26. MathWorld-A Wolfram Web Resource Website. Available: http://mathworld. wolfram.com/SphericalCap.html. Accessed 2013 Aug 2.
27. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H (2003) Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 42: 1089-1105.
28. Jordan BF, Sonveaux P (2012) Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front Pharmacol 3: 94.
29. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664.
30. Dewhirst MW (2009) Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172: 653-665.
31. Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, et al. (2011) Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Human gene therapy 22: 1343-1353.
32. Melcher A, Gough M, Todryk S, Vile R (1999) Apoptosis or necrosis for tumor immunotherapy: what's in a name? Journal of molecular medicine 77: 824-833.